Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaip.2023.09.043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nineteen-Month Immunity to Adverse Radiation Effects Following 5-Fraction Re-radiosurgery With 43.6 Gy for Local Progression After Prior 3-Fraction Radiosurgery for Brain Metastasis From Pan-Negative Lung Adenocarcinoma.
Cureus
October 2023
Department of Radiology, Aichi Medical University, Nagakute, JPN.
Clinical management of patients with local control failure following stereotactic radiosurgery (SRS) for brain metastasis (BM) can be frequently challenging. Re-irradiation with multi-fraction (fr) SRS by using a biological effective dose of ≥80 Gy, based on the linear-quadratic formula with an alpha/beta ratio of 10 (BED), can be an efficacious option for such a scenario with the BED of <80 Gy. However, its long-term safety beyond one year remains unclear.
View Article and Find Full Text PDFPersistent nivolumab-induced urticaria with vibratory and delayed-pressure angioedema.
J Allergy Clin Immunol Pract
January 2024
Université Paris-Saclay, UVSQ, EA4340-BECCOH, AP-HP, Department of General and Oncologic Dermatology, Ambroise-Paré Hospital, Boulogne-Billancourt, France. Electronic address:
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma.
J Oncol Pharm Pract
March 2023
Department of Hematology, Troyes General Hospital, Troyes, France.
Introduction: Nivolumab, the monoclonal antibody inhibitor of programmed cell death protein 1, enhances the T-cell response, including anti-tumour responses, by blocking the attachment of programmed death-ligand 1 and programmed death-ligand 2 ligands to the programmed cell death protein 1 receptor, which in turn leads to a reduction in tumour growth. Nivolumab has been approved in relapsed or refractory classic Hodgkin's lymphoma after autologous transplantation of haematopoietic stem cell and treatment with brentuximab as monotherapy.
Case Report: We herewith report a case of 65-year-old woman who developed an interstitial pneumonitis and a global cardiac hypokinesis following a treatment with Nivolumab for a refractory Hodgkin's Lymphoma.
A novel report of nivolumab-induced transient and persistent acantholytic dermatosis associated with multiple cutaneous toxicities in a patient with metastatic melanoma.
Acta Oncol
June 2022
Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY, USA.
Severe oral ulcerative and lichenoid lesions associated with adrenal insufficiency in a patient treated with nivolumab: Report of a case and review of literature.
Spec Care Dentist
May 2022
Pathology Department, School of Dentistry, University of São Paulo, São Paulo, Brazil.
Nivolumab, an antibody against anti-programmed death type 1, has been used for treatment of advanced non-small cell lung cancer with improvement of overall survival. Usually, diarrhea, cutaneous rash, and pruritus are reported as the most common immune-related adverse effects of nivolumab therapy. Oral lesions and secondary adrenal insufficiency sometimes occur but usually are rare events.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!